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Abstract  
Degradable polymer prodrugs based on gemcitabine (Gem) as an anticancer drug were 
synthesized by ’drug-initiated’ nitroxide-mediated radical ring-opening copolymerization 
(NMrROP) of methacrylic esters and 2-methylene-4-phenyl-1,3-dioxolane (MPDL). Different 
structural parameters were varied to determine the best biological performances: the nature of 
the monomer [i.e., oligo(ethylene glycol) methacrylate (OEGMA) or methyl methacrylate 
(MMA)], the nature of the Gem-polymer linker (i.e., amide or amide and diglycolate) and the 
MPDL content in the copolymer. Depending on the nature of the methacrylate monomer, two 
small libraries of water-soluble copolymer prodrugs and nanoparticles were obtained (Mn ~ 
10000 g.mol
-1
, Ð = 1.1–1.5), that exhibited tunable hydrolytic degradation under accelerated 
conditions governed by the MPDL content. Drug-release profiles in human serum and in vitro 
anticancer activity on different cell lines enabled preliminary structure-activity relationships 
to be established. The cytotoxicity was independently governed by: (i) the MPDL content –
the lower the MPDL content, the greater the cytotoxicity; (ii) the nature of the linker –the 
presence of a labile diglycolate linker enabled a greater Gem release compared to a simple 
amide bond and (iii) the hydrophilicity of the methacrylate monomer –OEGMA enabled a 
greater anticancer activity to be obtained compared to MMA-based polymer prodrugs. 
Remarkably, the optimal structural parameters enabled to reach the cytotoxic activity of the 
parent (free) drug.  
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Introduction 
In the field of nanomedicine, drug-loaded polymer nanocarriers is considered as a promising 
strategy to improve the efficacy of drugs such as chemotherapeutics.
1,2
 Traditionally, drugs 
are physically encapsulated during the nanocarrier formulation and thus simply entrapped into 
the polymer matrix. These drug delivery systems lead to protection of the drug from rapid 
metabolization, to longer circulation time, to lower toxicity toward healthy cells/tissues and 
open the door to active targeting by their surface-functionalization using biologically active 
ligands. Despite major advances and encouraging results, important limitations remain that 
may explain the small number of marketed nanomedicines and recent clinical trial 
disappointments: (i) the “burst-release”; that is the quick and uncontrolled release of a 
significant fraction of the drug post-injection; (ii) the poor drug-loadings, usually only a few 
percent and (iii) the crystallization of some drugs into the polymer matrix. These three 
different events can lead to prohibitive toxicity and/or colloidal instability of the nanocarriers. 
The prodrug strategy, which consists in coupling the drug to the nanocarrier, can be 
used to circumvent, or at least alleviate, the above-mentioned issues.
3
 Among the different 
synthetic pathways to produce polymer prodrug nanocarriers, the most used are certainly the 
“grafting to” and “grafting from” approaches that consist in functionalization of preformed 
polymer or monomer, respectively. The emerging “grafting through” strategy (also called 
“drug-initiated”), that relies on the controlled growth of a short polymer chain from a drug, 
used as an initiator, possesses appealing benefits:
4
 (i) the synthesis and purification are simple 
because a few synthetic steps are necessary; (ii) the resulting materials have a simple, well-
defined structure (one drug attached at the extremity of each polymer chain); (iii) high drug 
loadings can be easily reached by targeting short polymer chains; (iv) this approach can be 
applied to different pathologies simply by changing the nature of the drug and (v) the 
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properties of the resulting polymer prodrug can be finely tuned by changing the nature of the 
growing polymer.  
The robustness of the drug-initiated method has been illustrated by its application to 
the synthesis of a variety of different polymer prodrugs constructed by either ring-opening 
polymerization (ROP)
5-9
 or reversible-deactivation radical polymerization (RDRP),
10-18
 
including nitroxide-mediated radical polymerization (NMP)
19
 or reversible addition-
fragmentation chain transfer (RAFT) polymerization.
20
 Whereas ROP generated degradable 
polyester prodrug nanocarriers, they exhibited poor colloidal stability and required post-
stabilization by means of macromolecular surfactants, which is a major drawback. Also, no in 
vivo anticancer activity has been reported from these systems. On the other hand, RDRP-
constructed polymer prodrugs gave promising anticancer efficacy in vivo, relied on simpler 
polymerization methods (e.g., no stringent conditions, commercially available controlling 
agents) and offered much more versatility regarding the nature of the polymer used. However, 
they are not degradable because of the carbon-carbon backbone of the vinyl polymer chains. 
This represents an important drawback because non-degradable materials may accumulate in 
the body, leading to prohibitive toxicity in case chronic/repeated administration is envisioned. 
A global strategy combining both the advantages of ROP and RDRP for the design of 
efficient polymer prodrugs by the “drug-initiated” approach is thus highly desirable. 
Conferring degradability to vinyl materials is currently the focus of intensive work.
21
 
This research topic is crucial given the numerous systems based on vinyl polymers devoted to 
biomedical applications regularly being reported in the literature. Among the different 
synthetic strategies, radical ring-opening polymerization (rROP) appears to be the method of 
choice for incorporating labile groups into the polymer backbone and enabling significant 
degradation.
22,23
 Thanks to its radical ring-opening mechanism, rROP possesses both the 
versatility and simplicity of radical polymerization, together with the ability to introduce 
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functional groups into the polymer backbone. Among the different classes of monomers that 
have been polymerized by rROP, cyclic ketene acetals (CKA) are the most-studied family. 
Although their homopolymerization have been extensively studied in the 80s,
24-27
 they 
aroused renewed interest over the past decade as comonomers to confer degradability to vinyl 
polymers via insertion of ester groups from either free-radical copolymerization
28-34
 or 
RDRP.
32,35-45
 Other cyclic monomers deriving from cyclic allylic sulfides
46-48
 have also been 
used to incorporate cleavable ester, thioester, and disulfide functionalities into the polymer 
backbone through RAFT copolymerization with traditional vinyl monomers.
41
 Despite several 
applications of rROP-designed materials for biomedical applications,
31,49-51
 their use in the 
field of prodrug nanocarriers has only been reported from preformed functional copolymers 
via the “grafting to” approach.52,53  
Herein, we report for the first time on a general approach that combines the best of two 
worlds; that is the drug-initiated synthesis of degradable polymer prodrug by rROP. We 
demonstrated that well-defined, degradable vinyl copolymers can be synthesized from an 
anticancer drug-bearing RDRP initiator by rROP, leading to nanocarriers, either water-soluble 
conjugates or nanoparticles (Figure 1), with adjustable anticancer activity depending on the 
nature of both the drug-polymer linkage and the copolymer. Not only this new class of 
polymer prodrugs overcame a significant obstacle in the field, but it also disclosed important 
insights into the relevant parameters that govern the drug release kinetics and eventually the 
anticancer activity.  
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Figure 1. Synthetic strategy for the design of degradable Gemcitabine-based polymer 
prodrugs by “drug-initiated” nitroxide-mediated radical ring-opening copolymerization 
(NMrROP). 
 
Experimental section 
Material 
Gemcitabine (> 98%) was purchased from Carbosynth Limited (UK). Oligo(ethylene glycol) 
methyl ether methacrylate (MeOEGMA, Mn = 300 g.mol
-1
), styrene (S, 99%), methyl 
methacrylate (MMA, 99%) and toluene (anhydrous, 99.8%) were purchased from Sigma-
Aldrich (France) and used as received (except for MMA which was distilled under reduced 
pressure). 2-Methylene-4-phenyl-1,3-dioxolane (MPDL),
54
 4-amino-1-[4-(tert-butyl-
dimethylsilanyloxy)-5-(tert-butyl-dimethyl-silanyloxymethyl)-3,3-difluorotetrahydro-furan-2-
yl]-1H-pyrimidin-2-one (TBDMS-Gem),
15
 and alkoxyamines Gem-AMA-SG1
10
 and AMA-
digly
11 
were prepared as reported elsewhere. Tetrabutylammonium fluoride (TBAF) was 
purchased from Alfa Aesar (A Johnson Matthey Co., France). Perfluoro-15-Crown-5-Ether 
(PFCE) was obtained from FluoroChem (UK). All other reactants were purchased from 
Sigma-Aldrich at the highest available purity and used as received. Deuterated chloroform 
(CDCl3) and dimethyl sulfoxide (DMSO-d6) were obtained from Eurisotop. All other solvents 
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were purchased from Carlo-Erba. Dulbecco's modified eagle's medium (DMEM) and fetal 
bovine serum (FBS) were purchased from Dulbecco (Invitrogen, France). Penicillin and 
streptomycin were obtained from Lonza (Verviers, Belgium). The 2-methyl-2-[N-tert-butyl-N-
(1-diethoxyphosphoryl-2,2-dimethylpropyl) aminoxy]propionic acid alkoxyamine 
(BlocBuilder MA, 99%) and the N-tert-butyl-N-(1-diethylphosphono-2,2-dimethylpropyl) 
nitroxide (SG1, 85%) were kindly supplied by Arkema. 
 
Analytical method 
Nuclear magnetic resonance (NMR) spectroscopy. NMR spectroscopy was performed in 5 
mm diameter tubes in CDCl3 at 25 °C. 
1
H NMR or 
13
C NMR spectroscopy were performed on 
a Bruker Avance 300 spectrometer at 300 MHz (
1
H) or 75 MHz (
13
C). The chemical shift 
scale was calibrated based on the internal solvent signals. 
19
F NMR spectra were recorded on 
a Bruker Avance 400 at 376.5 MHz.  The chemical shift scale was calibrated relative to an 
internal standard (PFCE, δ = - 88 ppm). 
Mass Spectrometry (MS). Mass spectra were recorded with a Bruker Esquire-LC instrument. 
High-resolution (HR) mass spectra (electron spin ionization, ESI) were recorded on a 
ESI/TOF (LCT, Waters) LC-spectrometer. Elemental analyses were performed by the Service 
de microanalyse, Centre d’ tudes  harmaceuti ues   h tenay-Malabry, France, with a 
PerkinElmer 2400 analyzer. 
Size exclusion chromatography (SEC). SEC was performed at 30 °C with two columns 
from Polymer Laboratories (PL-gel MIXED-D; 300 × 7.5 mm; bead diameter  5 μm; linear 
part  400−400 000 g.mol-1) and a differential refractive index detector (Spectrasystem RI-150 
from Thermo Electron Corp.), using chloroform (CHCl3) as eluent at a flow rate of 1 
mL.min
−1
. Toluene was used as a flow-rate marker. The conventional calibration curve was 
based on poly(methyl methacrylate) (PMMA) standards (peak molar masses, Mp = 625−625 
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500 g.mol
−1
) from Polymer Laboratories. This technique allowed Mn (number-average molar 
mass), Mw (weight-average molar mass), and Mw/Mn (dispersity, Đ) to be determined. 
Dynamic light scattering (DLS) and zeta potential. Nanoparticle diameters (Dz) and zeta 
potentials (ζ) were measured by dynamic light scattering (DLS) with a Nano ZS from 
Malvern (173° scattering angle) at a temperature of 25 °C. The surface charge of the 
nanoparticles was determined by ζ-potential (mV) measurement at 25 °C after dilution with 1 
mM NaCl, using the Smoluchowski equation. 
Cryogenic transmission electron microscopy (cryo-TEM). The morphology of the 
nanoassemblies was observed by cryo-T M. Briefly  5 μL of the nanoparticle suspension (0.5 
mg.mL
-1
) was deposited on a Lacey Formvar/carbon 300 mesh copper microscopy grid (Ted 
Pella). Most of the drop was removed with a blotting filter paper and the residual thin film 
remaining within the holes was vitrified by plunging into liquid ethane. Samples were then 
observed using a JEOL 2100HC microscope. 
 
Synthetic procedures 
Synthesis of Gem-digly-AMA-SG1. TBDMS-Gem (3.0 g, 6.1 mmol), AMA-digly (2.5 g, 4.7 
mmol) and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 
3.2 g, 6.1 mmol) were dissolved in 30 mL of dry DMF. N,N-Diisopropylethylamine (DIPEA, 
2.2 mL, 12.4 mmol) was added dropwise. After stirring at 30 °C for 24 h under nitrogen 
atmosphere, the mixture was poured into 200 mL of EtOAc. The organic phase was washed 
with 1 M HCl, sat. NaHCO3 aqueous solution, and brine before being dried over MgSO4. The 
residue was concentrated under reduced pressure and purified by flash chromatography (SiO2, 
gradient elution from EtOAc/Petroleum Ether = 1/1, v/v to EtOAc) to give 2.01 g of Gem-
digly-AMA-SG1 as a white/slightly orange solid (Figure S1). Yield = 42 %. 
1
H NMR 
(CDCl3, 300 MHz): Major diastereomer: δ = 8.11 (1H, s, H6), 7.41 (1H, s, H5), 6.36 (1H, s, 
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H1’), 4,60 (1H, q, Hb), 3.75-4.50 (16H, m, Ha, Hg, H3’, H4’, H5’), 3.26 (1H, d, Hf), 1.48 (3H, d, 
Hc), 1.29 (6H, t, Hh), 1.10 (18H, s, He), 0.90 (18H, s, Hi), 0.13 (12H, s, Hj) ppm. Minor 
diastereomer: δ = 8.10 (1H, s, H6), 7.43 (1H, s, H5), 6.34 (1H, s, H1’), 4,60 (1H, q, Hb), 3.75-
4.50 (16H, m, Ha, Hg, H3’, H4’, H5’), 3.35 (1H, d, Hf), 1.50 (3H, d, Hc), 1.29 (6H, t, Hh), 1.15 
(18H, s, He), 0.95 (18H, s, Hi), 0.10 (12H, s, Hj) ppm.  
13
C NMR (CDCl3, 75 MHz): Major 
diastereomer: δ = 173.6 (s, Cd), 169.4 (s, Ck), 169.2 (s, Cj), 161.8 (s, C4), 154.9 (s, C2), 144.3 
(s, C6), 121.9 (s, C2’), 96.5 (s, C5), 84.9 (d, C1’), 82.3 (s, Cb), 81.4 (s, C4‘), 70.9 (s, Ca), 70.2 (t, 
C3’), 68.0 (s, Ca), 63.0 (s, C5’), 61.7 (t, Cg), 60.0 (s, Ca), 58.9 (d, Cg), 35.5 (d, Cl), 29.6 (d, Cg), 
27.9 (s, Ce), 25.7 (d, Ce), 19.3 (s, Cc), 18.3 (s, Ci), 17.9 (s, Cm), 16.5 (d, Ch) ppm. Minor 
diastereomer: δ = 172.6 (s, Cd), 169.3 (s, Ck), 169.1 (s, Cj), 161.9 (s, C4), 154.9 (s, C2), 144.2 
(s, C6), 121.9 (s, C2’), 96.6 (s, C5), 84.4 (d, C1’), 82.3 (s, Cb), 81.5 (s, C4‘), 70.9 (s, Ca), 69.5 (t, 
C3’), 68.3 (s, Ca), 63.0 (s, C5’), 62.0 (t, Cg), 60.0 (s, Ca), 59.1 (d, Cg), 35.2 (d, Cl), 30.1 (d, Cg), 
28.0 (s, Ce), 25.7 (d, Ce), 19.3 (s, Cc), 18.3 (s, Ci), 18.0 (s, Cm), 16.2 (d, Ch) ppm. 
19
F NMR 
(CDCl3, 376.5 MHz): δ = - 117 ppm. MS (ESI-): m/z = 999.5 (M-H)
-
. Calc. for 
C43H79F2N4O14PSi2: 1001. 
Synthesis of Gem-poly[(oligo(ethylene glycol) methyl ether methacrylate)-co-(2-
methylene-4-phenyl-1,3-dioxolane)] (Gem-P(OEGMA-co-MPDL)). A typical solution 
copolymerization procedure (fMPDL,0 = 0.2, expt. 1) is described as follows. In a 7-mL vial 
fitted with a rubber septum and a magnetic stirring bar, a mixture of OEGMA (1.3214 g, 4.40 
mmol, Mn = 300 g.mol
-1
), MPDL (0.1786 g, 1.10 mmol), Gem-AMA-SG1 (28.0 mg, 4.58 × 
10
-2
 mmol), SG1 (1.5 mg, 4.39 × 10
-3
 mmol) and anhydrous toluene (1.5 g, 1.73 mL) was 
degassed under stirring by argon bubbling for 15 min at room temperature. The mixture was 
then immersed in a preheated oil bath at 90 °C, corresponding to the time zero of the reaction 
(according to the small volume of solution and its quasi-instantaneous heating). Samples were 
periodically taken to monitor the OEGMA conversion by 
1
H NMR spectroscopy and the 
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macromolecular characteristics (Mn and Ð) by SEC. The copolymer was then precipitated 
twice in a mixture of cold cyclohexane/petroleum ether (1/1, v/v) and dried under high 
vacuum until constant weight. The same procedure was followed by adapting the amount of 
the reactants for fMPDL,0 = 0.4 (expt. 2) [OEGMA (1.1028 g, 3.68 mmol), MPDL (0.3972 g, 
2.45 mmol), Gem-AMA-SG1 (23.0 mg, 3.76 × 10
-2
 mmol) and SG1 (1.3 mg, 3.80 × 10
-3
 
mmol)] and fMPDL,0 = 0.7 (expt. 3) [OEGMA (0.6633 g, 2.21 mmol), MPDL (0.8367 g, 5.17 
mmol), Gem-AMA-SG1 (13.8 mg, 2.31 × 10
-2
 mmol) and SG1 (0.8 mg, 2.34 × 10
-3
 mmol)].  
Synthesis of Gem-digly-poly[(oligo(ethylene glycol) methyl ether methacrylate)-co-(2-
methylene-4-phenyl-1,3-dioxolane)] (Gem-digly-P(OEGMA-co-MPDL)). A typical 
solution copolymerization procedure (fMPDL,0 = 0.2, expt. 1d) is as follows. In a 7-mL vial, 
fitted with a rubber septum and a magnetic stirring bar, a mixture of OEGMA (1.3214 g, 4.40 
mmol), MPDL (0.1786 g, 1.10 mmol), Gem-digly-AMA-SG1 (45.0 mg, 4.50 × 10
-2
 mmol), 
SG1 (1.5 mg, 4.39 × 10
-3
 mmol) and anhydrous toluene (1.5 g, 1.73 mL) was degassed under 
stirring by argon bubbling for 15 min at room temperature. The mixture was then immersed in 
a preheated oil bath at 90 °C. Samples were periodically taken to monitor the OEGMA 
conversion by 
1
H NMR spectroscopy and the macromolecular characteristics (Mn and Ð) by 
SEC. The copolymer was then precipitated twice in a mixture of cold cyclohexane/petroleum 
ether (1/1, v/v) and dried under high vacuum until constant weight. The same procedure was 
followed by adapting the amount of the reactants for fMPDL,0 = 0.4 (expt. 2d) [OEGMA 
(1.1028 g, 3.68 mmol), MPDL (0.3972 g, 2.45 mmol), Gem-digly-AMA-SG1 (38.0 mg, 3.80 
× 10
-2
 mmol) and SG1 (1.3 mg, 3.80 × 10
-3
 mmol)] and fMPDL,0 = 0.7 (expt. 3d) [OEGMA 
(0.6633 g, 2.21 mmol), MPDL (0.8367 g, 5.17 mmol), Gem-digly-AMA-SG1 (23.0 mg, 2.30 
× 10
-2
 mmol) and SG1 (0.8 mg, 2.34 × 10
-3
 mmol)]. 
Synthesis of Gem-poly[(methyl methacrylate)-co-(2-methylene-4-phenyl-1,3-dioxolane)] 
(Gem-P(MMA-co-MPDL)). A typical solution copolymerization procedure (fMPDL,0 = 0.2, 
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expt. 4) is as follows. In a 7-mL vial, fitted with a rubber septum and a magnetic stirring bar, a 
mixture of MMA (1.0673 g, 10.67 mmol), MPDL (0.4327 g, 2.67 mmol), Gem-AMA-SG1 
(22.0 mg, 3.59 × 10
-2
 mmol), SG1 (1.3 mg, 3.80 × 10
-3
 mmol) and anhydrous toluene (1.5 g, 
1.73 mL) was degassed under stirring by argon bubbling for 15 min at room temperature. The 
mixture was then immersed in a preheated oil bath at 90 °C. Samples were periodically taken 
to monitor the MMA conversion by 
1
H NMR spectroscopy and the macromolecular 
characteristics (Mn and Ð) by SEC. The copolymer was then precipitated twice in cold MeOH 
and dried under high vacuum until constant weight. The same procedure was followed by 
adapting the amount of the reactants for fMPDL,0 = 0.4 (expt. 5)  [MMA (0.7215 g, 7.22 mmol), 
MPDL (0.7785 g, 4.81 mmol), Gem-AMA-SG1 (15.0 mg, 2.45 × 10
-2
 mmol) and SG1 (0.9 
mg, 2.49 × 10
-3
 mmol)] and fMPDL,0 = 0.7 (expt. 6) [MMA (0.3135 g, 3.14 mmol), MPDL 
(1.1865 g, 7.32 mmol), Gem-AMA-SG1 (6.5 mg, 1.06 × 10
-2
 mmol) and SG1 (0.4 mg, 1.02 × 
10
-3
 mmol)]. 
Synthesis of Gem-digly-poly[(methyl methacrylate)-co-(2-methylene-4-phenyl-1,3-
dioxolane)] (Gem-digly-P(MMA-co-MPDL)). A typical solution copolymerization 
procedure (fMPDL,0 = 0.2, expt. 4d) is as follows. In a 7-mL vial, fitted with a rubber septum 
and a magnetic stirring bar, a mixture of MMA (1.0673 g, 10.67 mmol), MPDL (0.4327 g, 
2.67 mmol), Gem-digly-AMA-SG1 (36.0 mg, 3.60 × 10
-2
 mmol), SG1 (1.3 mg, 3.80 × 10
-3
 
mmol) and anhydrous toluene (1.5 g, 1.73 mL) was degassed under stirring by argon bubbling 
for 15 min at room temperature. The mixture was then immersed in a preheated oil bath at 90 
°C. Samples were periodically taken to monitor the MMA conversion by 
1
H NMR 
spectroscopy and the macromolecular characteristics (Mn and Ð) by SEC. The copolymer was 
then precipitated twice in cold MeOH and dried under high vacuum until constant weight. The 
same procedure was followed by adapting the amount of the reactants for fMPDL,0 = 0.4 (expt. 
5d) [MMA (0.7215 g, 7.22 mmol), MPDL (0.7785 g, 4.81 mmol), Gem-digly-AMA-SG1 
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(25.0 mg, 2.5 × 10
-2
 mmol) and SG1 (0.9 mg, 2.49 × 10
-3
 mmol)] and fMPDL,0 = 0.7 (expt. 6d) 
[MMA (0.3135 g, 3.14 mmol), MPDL (1.1865 g, 7.32 mmol), Gem-digly-AMA-SG1 (10.5 
mg, 1.05 × 10
-2
 mmol) and SG1 (0.4 mg, 1.02 × 10
-3
 mmol)].  
Synthesis of low molar mass Gem-poly[(oligo(ethylene glycol) methyl ether 
methacrylate)-co-(2-methylene-4-phenyl-1,3-dioxolane)] (Gem-P(OEGMA-co-MPDL)). 
Copolymers with targeted Mn of ~10 000 g.mol
-1
 were prepared by following a similar 
procedure as for expt. 1 but with a polymerization time of 8 h. Experimental conditions were 
as follows: P1 (fMPDL,0 = 0.2) [OEGMA (1.7618 g, 5.87 mmol), MPDL (0.2382 g, 1.47 
mmol), Gem-AMA-SG1 (200.0 mg, 3.27 × 10
-1
 mmol), SG1 (12 mg, 3.51 × 10
-2
 mmol) and 
anhydrous toluene (2.0 g, 2.31 mL)], P2 (fMPDL,0 = 0.4) [OEGMA (1.4704 g, 4.90 mmol), 
MPDL (0.5296 g, 3.27 mmol), Gem-AMA-SG1 (205.0 mg, 3.35 × 10
-1
 mmol), SG1 (12 mg, 
3.51 × 10
-2
 mmol) and anhydrous toluene (2.0 g, 2.31 mL)] and P3 (fMPDL,0 = 0.7) [OEGMA 
(0.8862 g, 2.95 mmol), MPDL (1.1138 g, 6.88 mmol), Gem-AMA-SG1 (65.0 mg, 1.06 × 10
-1
 
mmol), SG1 (3.6 mg, 1.05 × 10
-2
 mmol) and anhydrous toluene (2.0 g, 2.31 mL)]. Final 
composition of the prodrug was determined by comparing the methoxy protons of OEG from 
OEGMA (at 3.4 ppm) to the aromatic protons of MPDL (at 7.2 ppm). The presence of Gem 
was quantitatively confirmed by 
19
F NMR by comparing the integration of the fluorine atoms 
of the internal standard PFCE (δ = - 88 ppm) and of Gem (δ = - 117 ppm).  Copolymers with 
lower targeted Mn were prepared (Table S1) by following a similar procedure as for P3: P3’ 
(targeted Mn = 9 000 g.mol
-1
, fMPDL,0 = 0.7) [OEGMA (0.8955 g, 2.99 mmol), MPDL (1.113 g, 
6.87 mmol), Gem-AMA-SG1 (65.9 mg, 0.11 mmol), SG1 (4.1 mg, 1.20 × 10
-2
 mmol) and 
anhydrous toluene (2.0 g, 2.31 mL)] and P3’’ (targeted Mn = 3 500 g.mol
-1
, fMPDL,0 = 0.7) 
[OEGMA (0.9328 g, 3.11 mmol), MPDL (1.205 g, 7.44 mmol), Gem-AMA-SG1 (187.8 mg, 
0.31 mmol), SG1 (9.7 mg, 2.84 × 10
-2
 mmol) and anhydrous toluene (2.0 g, 2.31 mL)].  
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Synthesis of low molar mass Gem-digly-poly[(oligo(ethylene glycol) methyl ether 
methacrylate)-co-(2-methylene-4-phenyl-1,3-dioxolane)] (Gem-digly-P(OEGMA-co-
MPDL)). Copolymers with targeted Mn of ~10 000 g.mol
-1
 were prepared by following a 
similar procedure as for expt. 1 but with a polymerization time of 8 h. Experimental 
conditions were as follows: P1d (fMPDL,0 = 0.2) [OEGMA (0.8805 g, 2.93 mmol), MPDL 
(0.1195 g, 0.74 mmol), Gem-digly-AMA-SG1 (266.6 mg, 2.66 × 10
-1
 mmol), SG1 (9 mg, 
2.63 × 10
-2
 mmol) and toluene (1.0 g, 1.15 mL)], for P2d (fMPDL,0 = 0.4) [OEGMA (0.7375 g, 
2.46 mmol), MPDL (0.2660 g, 1.64 mmol), Gem-digly-AMA-SG1 (93.3 mg, 9.32 × 10
-2
 
mmol), SG1 (3.2 mg, 9.36 × 10
-3
 mmol) and toluene (1.0 g, 1.15 mL)] and for P3d (fMPDL,0 = 
0.7) [OEGMA (0.4420 g, 1.47 mmol), MPDL (0.5580 g, 3.44 mmol), Gem-digly-AMA-SG1 
(53.3 mg, 5.33 × 10
-2
 mmol), SG1 (1.7 mg, 4.89× 10
-3
 mmol) and toluene (1.0 g, 1.15 mL)]. 
Final composition of the prodrug was determined by comparing the methoxy protons of OEG 
from OEGMA (at 3.4 ppm) to the aromatic protons of MPDL (at 7.2 ppm). The presence of 
Gem was quantitatively confirmed by 
19
F NMR by comparing the integration of the fluorine 
atoms of the internal standard PFCE (δ = - 88 ppm) and of Gem (δ = - 117 ppm). 
Synthesis of low molar mass Gem-poly[(oligo(ethylene glycol) methyl ether 
methacrylate)-co-styrene] (Gem-P(OEGMA-co-S)). Polymer prodrug without MPDL with 
targeted Mn of ~10 000 g.mol
-1
 were prepared by following a similar procedure as for expt. 1 
but with a polymerization time of 8 h. Experimental conditions were as follows: OEGMA 
(1.4436 g, 4.81 mmol), S (0.0563 g, 5.41 × 10
-1
 mmol), Gem-AMA-SG1 (7.0 mg, 1.14 × 10
-1
 
mmol), and anhydrous toluene (1.5 g, 1.73 mL). SEC: Mn = 10300 g.mol
-1
, Mw/Mn = 1.29.  
Synthesis of low molar mass poly[(oligo(ethylene glycol) methyl ether methacrylate)-co-
(2-methylene-4-phenyl-1,3-dioxolane)] (P(OEGMA-co-MPDL)). Copolymers without 
Gem P7 with targeted Mn of ~10 000 g.mol
-1
 and fMPDL,0 = 0.4 were prepared by following a 
similar procedure as for expt. 1 but with a polymerization time of 8 h. Experimental 
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conditions were as follows: OEGMA (1.1028 g, 3.68 mmol), MPDL (0.3972 g, 2.45 mmol), 
BlocBuilder MA (15.0 mg, 3.94 × 10
-2
 mmol), and anhydrous toluene (1.5 g, 1.73 mL). Final 
composition of the copolymer was determined by comparing the terminal methoxy protons of 
pendant OEG for OEGMA (at 3.4 ppm) to the aromatic protons of MPDL (at 7.2 ppm). SEC: 
Mn = 12100 g.mol
-1
, Mw/Mn = 1.30. 
1
H NMR: FMPDL = 0.13.  
Synthesis of low molar mass Gem-poly[(methyl methacrylate)-co-(2-methylene-4-
phenyl-1,3-dioxolane)] (Gem-P(MMA-co-MPDL)). Copolymers with targeted Mn of 
~10 000 g.mol
-1
 were prepared by following a similar procedure as for expt. 4 but with a 
polymerization time of 5 h. Experimental conditions were as follows: P4 (fMPDL,0 = 0.2) 
[MMA (1.0673 g, 10.67 mmol), MPDL (0.4327 g, 2.67 mmol), Gem-AMA-SG1 (340.0 mg, 
5.56 × 10
-1
 mmol), SG1 (18.1 mg, 5.29 × 10
-2
 mmol) and anhydrous toluene (1.5 g, 1.73 
mL)], for P5 (fMPDL,0 = 0.4) [MMA (0.7215 g, 7.22 mmol), MPDL (0.7785 g, 4.81 mmol), 
Gem-AMA-SG1 (230 mg, 3.76 × 10
-1
 mmol), SG1 (12.3 mg, 3.60 × 10
-2
 mmol) and 
anhydrous toluene (1.5 g, 1.73 mL)] and for P6 (fMPDL,0 = 0.7) [MMA (0.3135 g, 3.14 mmol), 
MPDL (1.1865 g, 7.32 mmol), Gem-AMA-SG1 (30.0 mg, 4.90 × 10
-2
 mmol), SG1 (1.6 mg, 
4.69 × 10
-3
 mmol) and anhydrous toluene (1.5 g, 1.73 mL)]. Final composition of the prodrug 
was determined by comparing the methyl protons in α-position to the ester group of MMA (at 
3.7 ppm) to the aromatic protons of MPDL (at 7.2 ppm). The presence of Gem was 
quantitatively confirmed by 
19
F NMR by comparing the integration of the fluorine atoms of 
the internal standard PFCE (δ = - 88 ppm) and of Gem (δ = - 117 ppm). 
Synthesis of low molar mass Gem-digly-poly(methyl methacrylate)-co-(2-methylene-4-
phenyl-1,3-dioxolane) (Gem-digly-P(MMA-co-MPDL)). Copolymers with targeted Mn of 
~10 000 g.mol
-1
 were prepared by following a similar procedure as for expt. 4 but with a 
polymerization time of 5 h. Experimental conditions were as follows: P4d (fMPDL,0 = 0.2) 
[MMA (1.0673 g, 10.67 mmol), MPDL (0.4327 g, 2.67 mmol), Gem-digly-AMA-SG1 (152.0 
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mg, 1.52 × 10
-1
 mmol), SG1 (5.2 mg, 1.52 × 10
-2
 mmol) and anhydrous toluene (1.5 g, 1.73 
mL)] for P5d (fMPDL,0 = 0.4) [MMA (0.7215 g, 7.22 mmol), MPDL (0.7785 g, 4.81 mmol), 
Gem-digly-AMA-SG1 (100.0 mg, 9.99 × 10
-2 
mmol), SG1 (3.4 mg, 9.95 × 10
-3
 mmol) and 
anhydrous toluene (1.5 g, 1.73 mL)] and for P6d (fMPDL,0 = 0.7) [MMA (0.3135 g, 3.14 
mmol), MPDL (1.1865 g, 7.32 mmol), Gem-digly-AMA-SG1 (25 mg, 2.50 × 10
-2
 mmol), 
SG1 (0.9 mg, 2.63 × 10
-3
 mmol) and anhydrous toluene (1.5 g, 1.73 mL)]. Final composition 
of the prodrug was determined by comparing the methyl protons in α-position to the ester 
group of MMA (at 3.7 ppm) to the aromatic protons of MPDL (at 7.2 ppm). The presence of 
Gem was quantitatively confirmed by 
19
F NMR by comparing the integration of the fluorine 
atoms of the internal standard PFCE (δ = - 88 ppm) and of Gem (δ = - 117 ppm). 
Synthesis of low molar mass Gem-poly[(methyl methacrylate)-co-styrene] (Gem-
P(MMA-co-S)). Polymer prodrug without MPDL with targeted Mn of ~10 000 g.mol
-1
 were 
prepared by following a similar procedure as for expt. 4 but with a polymerization time of 5 h. 
Experimental conditions were as follows: MMA (1.3393 g, 13.39 mmol), S (0.1607 g, 15.45 
mmol), Gem-AMA-SG1 (2.81 mg, 4.59 × 10
-2
 mmol), and anhydrous toluene (1.5 g, 1.73 
mL). SEC: Mn = 9751 g.mol
-1
, Mw/Mn = 1.33. 
Synthesis of low molar mass poly[(methyl methacrylate)-co-(2-methylene-4-phenyl-1,3-
dioxolane)] (P(MMA-co-MPDL)). Copolymers without Gem P8 with targeted Mn of 
~10 000 g.mol
-1
 and fMPDL,0 = 0.7 were prepared by following a similar procedure as for expt. 
4 but with a polymerization time of 5 h. Experimental conditions were as follows: MMA 
(0.3604 g, 3.60 mmol), MPDL (0.4010 g, 2.47 mmol), BlocBuilder MA (16.0 mg, 4.20 × 10
-2
 
mmol), and anhydrous toluene (0.77 g, 0.89 mL). Final composition of the copolymer was 
determined by comparing the methyl protons in α-position to the ester group of MMA (at 3.7 
ppm) to the aromatic protons of MPDL (at 7.2 ppm). SEC: Mn = 9100 g.mol
-1
, Mw/Mn = 1.26. 
1
H NMR: FMPDL = 0.17. 
16 
 
Deprotection of the copolymers 
Deprotection of Gem-digly-P(OEGMA-co-MPDL). The TBDMS-protected Gem-digly-
P(OEGMA-co-MPDL) copolymer (100 mg) was dissolved in 0.5 mL THF and TBAF (1 M in 
THF  50 μL) was added. The solution was allowed to stir for 30 min and the solvent was 
removed under reduced pressure. After solubilization in 2 mL of DCM, the organic phase was 
washed twice with brine, precipitated in a mixture of cold cyclohexane/petroleum ether (1/1, 
v/v) and dried under reduced pressure. The copolymers were analyzed by 
1
H NMR and SEC. 
NMR analysis showed complete disappearance of TBDMS protecting groups (Figure S2) and 
19
F NMR confirmed the quantitative presence of Gem. 
Deprotection of Gem-digly-P(MMA-co-MPDL). The TBDMS-protected copolymer Gem-
digly-P(MMA-co-MPDL) (100 mg) was dissolved in 0.5 mL THF and TBAF (1 M in THF, 50 
μL) was added. The solution was allowed to stir for 30 min before pouring into 10 mL of 
MeOH. The copolymer was then precipitated cold MeOH and dried under high vacuum. 
Polymers were analyzed by 
1
H NMR and SEC. NMR analysis showed complete 
disappearance of TBDMS protecting groups (Figure S3) and 
19
F NMR confirmed the 
quantitative presence of Gem. 
 
Hydrolytic degradation 
Hydrolytic degradation of Gem-P(OEGMA-co-MPDL). In a 5-mL vial, 50 mg of 
copolymer were dissolved in 5 mL of 5% KOH aqueous solution and stirred at room 
temperature. Samples (1 mL) were periodically taken, neutralized with 1 M HCl aqueous 
solution and lyophilized. 2 mL of chloroform was then added, allowing the salts to be filtrated 
off. Finally, the solvent was removed under reduced pressure and the degradation products 
were analyzed by SEC. 
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Hydrolytic degradation of Gem-P(MMA-co-MPDL). In a 5-mL vial, 50 mg of copolymer 
was dissolved in 2.5 mL of THF. After solubilization, 2.5 mL of potassium hydroxide 
solution (KOH, 10%) in methanol was added. The cloudy mixture was stirred at room 
temperature. Samples (1 mL) were periodically taken, immediately dried under vacuum and 2 
mL of chloroform were added, allowing salts filtration. Finally, solvent was removed under 
reduced pressure and degradation products were analyzed by SEC. Note that the carboxylic 
acid chain ends after degradation can be responsible for aggregation of polymer chains during 
SEC analysis, resulting in larger apparent Mn. This problem was resolved by adding 0.1 % 
(w/w) of TFA in both the eluent and the sample. 
 
Nanoparticle preparation  
Nanoparticles were prepared by the nanoprecipitation technique.
55
 For Gem-P(MMA-co-
MPDL) and Gem-digly-P(MMA-co-MPDL), 2 mg of copolymer was dissolved in 2 mL of 
THF, and added dropwise to 4 mL MilliQ water under stirring. For Gem-P(OEGMA-co-
MPDL) and Gem-digly-P(OEGMA-co-MPDL), 2.5 mg of copolymer was dissolved in 0.5 
mL of THF, and added dropwise to 1 mL MilliQ water under stirring. In all cases, THF was 
evaporated at ambient temperature using a Rotavapor. Average diameter (Dz) and zeta 
potential () measurements were carried out in triplicate. For stability study, the different 
samples were either let in water, PBS or diluted in complete cell culture medium to reach a 
final concentration of 0.25 mg.mL
-1
. Samples were kept at 4 °C and let warm to room 
temperature before each measurement that was performed in triplicate at 25 °C. 
 
Nanoprecipitation yield  
The amount of Gem-P(OEGMA-co-MPDL) nanoparticles formed by nanoprecipitation was 
determined as followed. A minimal amount of 4 mL of nanoparticle suspension 
18 
 
(corresponding at least to 10 mg of copolymer) were ultracentrifugated (40 000 rpm, 4 h, 4 
°C). The supernatant and the pellet were separated and freeze-dried. The weight fraction of 
nanoparticles formed after nanoprecipitation was calculated according to: wnanoparticles = mpellet / 
(mpellet + msupernantant). 
 
Drug release kinetics  
To determine the release kinetics of Gem, 1.5 mL of Gem-P(OEGMA-co-MPDL) P1–P3 and 
P1d–P3d (0.5 mg.mL-1) or Gem-P(MMA-co-MPDL) P4–P6 and P4d–P6d (0.5 mg.mL-1) 
nanoparticles were added to 1.5 mL of human serum solution supplemented with 200 g.mL-1 
tetrahydrouridine (THU).
56,57
 The mixture was incubated at 37 °C and aliquots (600 µL) of 
incubation medium were withdrawn at different time points (1, 4, 8 and 24 h), spiked with 60 
µL of 10 µM Theophylline (Internal Standard, IS) before addition of 1 mL of a mixture of 
acetonitrile/methanol (90/10, v/v) and ultracentrifugated (15000 g, 20 min, 4 °C). The 
supernatant was then evaporated to dryness under a nitrogen flow at 30 °C. The released 
native drug was quantified by reverse-phase HPLC (Waters, Milford, MA 01757, USA) with 
a C18 column. To ensure that only native Gem was quantified, the calibration curve was 
carried out using native Gem (elution time = 10.6 min). For drug-release experiments, only 
this peak was integrated to determine native Gem content. Briefly, the chromatographic 
system consisted of a Waters 1525 Binary HPLC pump, a Waters 2707 Autosampler, a C18 
Uptisphere column (3 µm, 150 × 4.6 mm; Interchim), HPLC column temperature controllers 
(model 7950 column heater and chiller; Jones Chromatography, Lakewood, CO), and a 
Waters 2998 programmable photodiode-array detector. The HPLC column was maintained at 
30 °C and detection was monitored at 270 nm. The HPLC mobile phase consisted of a 
mixture of methanol and water with 0.05 M sodium acetate (pH 5.0, eluant A: 5/95, v/v; 
eluent B 97/3, v/v). The residues were dissolved in 100 µL of eluent A. Elution was 
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performed at a flow rate of 0.8 mL.min
-1
 isocratically for 8 min with eluent A followed by a 
linear gradient (1 min) to 100% eluent B. This was followed by a 15-min hold at eluent B and 
a 1 min linear gradient back to 100% eluent A. The system was held for 6 min for 
equilibration back to initial conditions. 
 
Biological Evaluation 
Cell lines and cell culture. Human pancreatic cancer cell line MiaPaCa-2 and human lung 
carcinoma cell line A549 were obtained from the American Type Culture Collection. All cell 
lines were maintained as recommended. Briefly, A549 and MiaPaCa-2 cells were grown in 
Dulbecco′s minimal essential medium (DMEM). All media were supplemented with 10% 
heat-inactivated FBS (56 °C, 30 min), penicillin (100 U.mL
-1) and streptomycin (100 μg.mL-
1
). Medium for MiaPaCa-2 cell line was supplemented with 2.5% heat-inactivated (56 °C, 30 
min) horse serum (Gibco). Cells were maintained in a humid atmosphere at 37 °C with 5% 
CO2.  
In vitro anticancer activity. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] was used to evaluate the cytotoxicity of the different polymer prodrugs. Briefly, 
cells (5 × 10
3
/well) were seeded in 96-well plates. After overnight incubation, the cells were 
then exposed to a series of concentrations of polymer prodrugs, control polymers or free Gem 
for 72 h (A549 cells) or 120 h (MiaPaCa-2 cells). 20 μL of MTT solution (5 mg.mL-1 in PBS) 
were then added for each well. The plates were incubated for 1 h at 37 °C and the medium 
was removed. 200 μL of DMSO were then added to each well to dissolve the precipitates. 
Absorbance was measured at 570 nm using a plate reader (Metertech Σ 960  Fisher Bioblock  
Illkirch, France). The percentage of surviving cells was calculated as the absorbance ratio of 
treated to untreated cells. The inhibitory concentration 50% (IC50) of the treatments was 
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determined from the dose-response curve. All experiments were set up in sextuplicate to 
determine means and SDs. 
 
Results and Discussions 
Synthetic strategy 
To illustrate our approach, gemcitabine (Gem, 2'-deoxy-2',2'-difluorocytidine) was selected as 
an anticancer drug. Gem is a nucleoside analog approved for the treatment of various solid 
tumors including lung, pancreatic, breast, or ovarian cancers.
58
 However, severe limitations 
restrict its clinical use and drastically reduce its efficacy: (i) short plasma half-life and rapid 
renal excretion due to rapid deamination by deoxycitidine deaminase, (ii) induction of 
resistances owing to inhibition of transmembrane transporter nucleoside, and (iii) severe side 
effects as a result of frequent administration schedule. Therefore, new prodrug strategies 
applied to Gem are of high importance in the field of nanomedicine. 
This new class of polymer prodrugs was synthesized by nitroxide-mediated radical 
ring-opening copolymerization (NMrROP) between a methacrylic ester and 2-methylene-4-
phenyl-1,3-dioxolane (MPDL) as a CKA, from a Gem-functionalized alkoxyamine initiator 
(Figure 1). This synthetic pathway was built upon our previous findings showing that MPDL, 
a 5-membered ring CKA, is a very attractive monomer that can be easily obtained and 
efficiently incorporated into a polymethacrylate backbone by NMrROP, resulting in well-
defined copolymers with controllable level of ester group insertion and up to nearly complete 
degradation upon hydrolysis.
54,59-61
  
To establish structure-activity relationships and obtain polymer prodrugs with the 
highest activity against cancer cells, various structural parameters were varied such as the 
nature of the methacrylic ester, the composition of the copolymer and the nature of the drug-
copolymer linker (Figure 2). More specifically, two different methacrylic ester monomers 
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were copolymerized with MPDL: either oligo(ethylene glycol) methyl ether methacrylate 
(OEGMA) as a hydrophilic monomer or methyl methacrylate (MMA) as a hydrophobic one 
(Figure 2a and c). Copolymerizations were initiated by two different alkoxyamines based on 
the SG1 nitroxide, which only differed in the nature of the linker between Gem and the 
alkoxyamine moiety: an amide bond (Gem-AMA-SG1) or an amide bond connected to a 
labile diglycolate linker (Gem-digly-AMA-SG1) (Figure 2b). Variable initial amounts of 
MPDL were also investigated to confer the resulting polymer prodrugs with distinct levels of 
degradability.  
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Figure 2. Synthesis of (a) Gem-P(OEGMA-co-MPDL) P1–P3 and Gem-P(MMA-co-MPDL) 
P4–P6 by NMrROP in toluene at 90 °C, (b) Gem-digly-AMA-SG1 by PyBOP-assisted 
coupling between TBDMS-Gem and digly-AMA-SG1 and (c) Gem-digly-P(OEGMA-co-
MPDL) P1d–P3d and Gem-digly-P(MMA-co-MPDL) P4d–P6d by NMrROP in toluene at 
90 °C followed by TBDMS group removal. 
  
Synthesis of Gem-based alkoxyamine initiators  
Given its susceptibility to deamination,
62
 Gem was derivatized through its C-4 amino group. 
Gem-AMA-SG1 was synthesized by direct coupling between unprotected Gem and AMA-
SG1 using PyBOP as a coupling agent. For Gem-digly-AMA-SG1, best conditions were 
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obtained via protection of the two hydroxyl group with TBDMSCl, followed by PyBOP-
assisted coupling of the resulting TBDMSGem with AMA-digly-SG1 (Figure 2b). The 
expected product (Figure S1) was obtained with a coupling yield of 63%.  
 
Copolymerization kinetics 
A comprehensive kinetic study was first performed to investigate the influence of the different 
parameters on the control of the copolymerization. Gem-AMA-SG1 or Gem-digly-AMA-SG1 
alkoxyamines where used to initiate the NMrROP of OEGMA (expts. 1–3 and 1d–3d, Figure 
3) or MMA (expts. 4–6 and 4d–6d, Figure 4) in presence of variable initial fraction of MPDL 
(fMPDL,0 = 0.2–0.7) at 90 °C in 50 wt.% toluene. In all cases, the higher the initial fraction of 
MPDL, the better the control of the copolymerization. For fMPDL,0 = 0.2, regardless of 
methacrylic ester used (expts. 1, 1d, 4 and 4d), the copolymerizations did not exhibit a first 
order kinetics while Mn values hardly increased with conversion and were much higher than 
the theoretical ones with rather high dispersities after 50% conversion, thus indicating a 
partial control. Such a low initial amount of MPDL was therefore not sufficient for efficient 
insertion of MPDL in the copolymer (according to the reactivity ratios) to prevent irreversible 
termination reactions. For fMPDL,0 = 0.4, (expts. 2, 2d, 5 and 5d), the control over the 
polymerization was significantly improved, leading to nearly first order kinetics, linear 
increase of Mn with conversion, exhibiting values closer to the theoretical ones, and lower 
dispersities even at high conversion for expts. 4–6 and 4d–6d. Control was further enhanced 
for fMPDL,0 = 0.7 (expt. 3, 3d, 6 and 6d).  
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Figure 3. NMrROP of OEGMA and MPDL in 50 wt.% toluene at 90 °C as a function of the 
nature of the alkoxyamine initiator [(a) and (b) Gem-AMA-SG1, (c) and (d) Gem-digly-
AMA-SG1] and the initial fraction of MPDL: ● expts. 1 and 1d (fMPDL,0 = 0.2), ■ expts. 2 
and 2d (fMPDL,0 = 0.4), ▲ expts. 3 and 3d (fMPDL,0 = 0.7). (a) and (c) Ln[1/(1-conv)] vs. time 
(conv = OEGMA conversion). Dashed lines connecting data points are guides for the eye 
only. (b) and (d) Number-average molar mass, Mn and dispersity, Mw/Mn, vs. conversion. The 
dashed black line represents the theoretical Mn.  
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Figure 4. NMrROP of MMA and MPDL in 50 wt.% toluene at 90 °C as a function of the 
nature of the alkoxyamine initiator [(a) and (b) Gem-AMA-SG1, (c) and (d) Gem-digly-
AMA-SG1] and the initial fraction of MPDL: ● expts. 4 and 4d (fMPDL,0 = 0.2), ■ expts. 5 
and 5d (fMPDL,0 = 0.4), ▲ expts. 6 and 6d (fMPDL,0 = 0.7). (a) and (c) Ln[1/(1-conv)] vs. time 
(conv = MMA conversion). Dashed lines connecting data points are guides for the eye only. 
(b) and (d) Number-average molar mass, Mn and dispersity, Mw/Mn, vs. conversion. The 
dashed black line represents the theoretical Mn.  
 
Interestingly, the control was generally better when the copolymerization was initiated by 
Gem-digly-AMA-SG1 compared to those initiated by Gem-AMA-SG1. Mn values and 
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dispersities at high conversions were indeed systematically lower with Gem-digly-AMA-SG1. 
This trend can be explained by the structure of the alkoxyamines and its influence on its 
dissociation rate constant and subsequently on the control of the polymerization. Conversely 
to Gem-digly-AMA-SG1, Gem-AMA-SG1 is prone to intramolecular hydrogen-bonding 
(IHB) between the hydrogen of the amide from the propagating radical and the nitroxide 
fragment.
63
 It resulted in a slower dissociation kinetics and thus a less efficient control 
because of a lower amount of released nitroxide. 
Synthesis of low molar mass polymer prodrugs for biological evaluations 
One of the main benefits of the drug-initiated method is the facile tuning of the drug loading 
simply by varying the Mn of the polymer, which is of great importance for further biological 
evaluation. Herein, we targeted lower molar mass polymer prodrugs (Mn ~10 000 g.mol
-1
) to 
obtain a drug loading of ~2.5 wt.% by adapting the reaction conditions (e.g., lower reaction 
times and/or lower targeted Mn, see experimental part). Note that, if needed, higher drug 
loadings can be successfully obtained (e.g., 3.6 and 9.0 wt.%) by further decreasing the Mn 
(P3’ and P3’’, Table S1). Four libraries of well-defined copolymer prodrugs from each series 
were prepared (Table 1 and Figure S4): Gem-P(OEGMA-co-MPDL) (P1–P3), Gem-digly-
P(OEGMA-co-MPDL) (P1d–P3d), Gem-P(MMA-co-MPDL) (P4–P6) and Gem-digly-
P(MMA-co-MPDL) (P4d–P6d). A lower reaction time also enabled improving the control by 
avoiding high monomer conversion and thus extensive occurrence of irreversible termination 
reactions. Overall, dispersities of the resulting copolymers ranged from 1.1–1.4, except for P1 
whose control was difficult to achieve given the very low amount of initial MPDL
59
 and the 
use of the less efficient alkoxyamine (as detailed in the previous section). 
1
H NMR 
spectroscopy of the purified copolymers (and deprotected for P1d–P6d) in CDCl3 (Figures 
S5–S8) and in DMSO-d6 (Figures S9–S12) showed all signals expected for each structure. 
19
F 
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NMR spectroscopy confirmed the quantitative presence of Gem at the extremity of the 
copolymers. 
 
Table 1. Experimental Conditions and Macromolecular Properties of Gem-based P(OEGMA-
co-MPDL) and P(MMA-co-MPDL) polymer prodrugs. 
Prodrug Alkoxyamine 
Methacrylic 
ester 
fMPDL, 0 
Conv.
a
 (%) 
/ Temps (h) 
Mn
b
  
(g/mol) 
Total 
DPn 
Ð
b FMPDL
c
  
P1 Gem-AMA-SG1 OEGMA 0.2 40 / 8 15 500 51 1.54 0.06 
P2 Gem-AMA-SG1 OEGMA 0.4 28 / 8 10 200 34 1.39 0.12 
P3 Gem-AMA-SG1 OEGMA 0.7 18 / 8 10 000 35 1.37 0.25 
P1d Gem-digly-AMA-SG1 OEGMA 0.2 61 / 8 11 500 36 1.24 0.07 
P2d Gem-digly-AMA-SG1 OEGMA 0.4 36 / 8 13 200 43 1.24 0.11 
P3d Gem-digly-AMA-SG1 OEGMA 0.7 22 / 8 11 200 38 1.13 0.22 
P4 Gem-AMA-SG1 MMA 0.2 35 / 5 13 200 119 1.27 0.10 
P5 Gem-AMA-SG1 MMA 0.4 34 / 5   9 900 83 1.28 0.19 
P6 Gem-AMA-SG1 MMA 0.7 23 / 5 10 300 82 1.21 0.29 
P4d Gem-digly-AMA-SG1 MMA 0.2 56 / 8 15 400 138 1.34 0.07 
P5d Gem-digly-AMA-SG1 MMA 0.4 55 / 8 12 400 106 1.29 0.12 
P6d Gem-digly-AMA-SG1 MMA 0.7 33 / 8 10 900 84 1.20 0.29 
a
 Methacrylic ester conversion determined by 
1
H NMR. 
b
 Determined by SEC after precipitation. 
c
 
Determined by 
1
H NMR.  
 
Despite unfavorable reactivity ratios of the different monomer pairs (rMPDL = 0 and rOEGMA = 
6.95,
59 
and rMPDL = 0.01 and rMMA = 4.0
54
), the molar fraction of MPDL in the copolymer 
(FMPDL) was finely tuned by varying the initial molar fraction of MPDL in the comonomer 
feed (Table 1) to induce different levels of degradability. On average, FMPDL was ~0.07 for 
fMPDL,0 = 0.2, ~0.13 for fMPDL,0 = 0.4 and ~0.26 for fMPDL,0 = 0.7.  
 
Hydrolytic degradation of the prodrugs 
The degradation of the different copolymer prodrugs was then evaluated under accelerated 
conditions to probe the presence of ester group in the polymer backbone; that is at room 
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temperature in 5 % KOH, either in water for OEGMA-based copolymers (P1–P3) or in a 
THF/MeOH (50:50, v/v) mixture for MMA-based copolymers (P4–P6). As expected, control 
copolymers without MPDL (FMPDL = 0), Gem-P(OEGMA-co-S) and Gem-P(MMA-co-S), 
gave no degradation as shown by their constant Mn over time. Conversely, MPDL-containing 
copolymer prodrugs led to adjustable degradation in direct relationship with their MPDL 
content, as shown by the shifts of the SEC chromatograms towards lower Mn values (Figure 
S13–S14). Whatever the nature of the methacrylic ester, the higher the MPDL content, the 
greater the degradation. The Mn decrease (Figure 5) spanned from 10–30% for copolymers 
with the lowest MPDL contents (P1 and P4) to ~70% for those with the highest amounts of 
MPDL (P3 and P6). These results confirmed the significant insertion of open MPDL units in 
the main chain of the copolymers and the possibility to fine-tune their degradation by 
adjusting the initial comonomer stoichiometry.  
 
Figure 5. Hydrolytic degradation under accelerated conditions (5% KOH) of the different 
degradable polymer prodrugs as a function of the MPDL fraction and the nature of the 
methacrylic ester monomer: (a) Gem-P(OEGMA-co-MPDL); ●  control (FMPDL = 0); ▲, P1 
(FMPDL = 0.06); ■  P2 (FMPDL = 0.12); ▼, P3 (FMPDL = 0.25). (b) Gem-P(MMA-co-M DL); ●  
control (FMPDL = 0); ▲, P4 (FMPDL = 0.10); ■  P5 (FMPDL = 0.19); ▼, P6 (FMPDL = 0.29). 
Dashed lines are guides for the eye only.  
 
Note that some discrepancy between theoretical Mn after degradation (calculated to according 
to: 1/FMPDL - 1) and experimental ones may appear because of unfavorable reactivity ratios, as 
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commonly observed with CKA monomers.
59
 Also, molar mass distributions stayed rather low 
(Ð ~1.5–1.8) after degradation, which is in agreement with a theoretical investigation64 
showing that stopping at low conversion for the synthesis of the copolymers is key to 
maintain a certain homogeneity of the degraded products.  
Physicochemical properties  
Given their hydrophobic backbone and the water-solubility of Gem, Gem-P(MMA-co-
MPDL) (P4–P6) and Gem-digly-P(MMA-co-MPDL) (P4d–P6d) prodrugs were formulated 
into nanoparticles in water. They displayed an average diameter in the 109–196 nm range, 
along with narrow particle size distributions (Table 2) and great colloidal stability in the long 
run either in water or in cell culture medium (Figure S15), whereas a poor colloidal stability 
was observed in PBS.  
 
Table 2. Characterization of Gem-P(MMA-co-MPDL) and Gem-digly-P(MMA-co-MPDL) 
Nanoparticles. 
Prodrug 
Dz
 a
 
(nm) 
PSD
a 
b 
(mV) 
%Gem
c
 
(wt. %) 
P4 196 0.09 -55 2.0 
P5 162 0.10 -57 2.6 
P6 174 0.09 -55 2.5 
P4d 109 0.13 -37 1.7 
P5d 110 0.11 -38 2.1 
P6d 117 0.10 -46 2.4 
a
 Determined by DLS. 
b
 Zeta potential, determined by the DLS apparatus. 
c
 Determined according to: 
%Gem = MWGem/Mn,SEC. 
 
Interestingly, nanoparticles prepared from P4d–P6d were significantly smaller than P4–P6, 
possibly because of the additional hydrophilicity provided by the diglycolate linker, 
promoting Gem positioning at the surface of the nanoparticles and thus inducing a more 
efficient stabilization. This hypothesis is supported by the increase of the predicted HLB 
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number for a model Gem-digly-PMMA prodrug compared to Gem-PMMA using both the 
Davies and the Griffin method (Table S2). Representative Cryo-TEM images showed 
spherical morphologies in good agreement with DLS data (Figure 6a-b and Figures S16-S17). 
All nanoparticles exhibited great colloidal stability over time as shown by their constant size 
and size distributions for at least 25 days after nanoprecipitation (Figure 6c). Such an efficient 
colloidal stability is likely the result of an efficient electrostatic stabilization, as shown by 
significantly negative zeta potential measurements (Table 2). 
 
 
Figure 6. Representative Cryo-TEM images of (a) Gem-P(MMA-co-MPDL) P6 and (b) 
Gem-digly-P(MMA-co-MPDL) P6d nanoparticles. (c) Evolution with time of the average 
diameter and the particle size distribution (PSD) of Gem-P(MMA-co-MPDL) (P4–P6) and 
Gem-digly-P(MMA-co-MPDL) (P4d–P6d) nanoparticles in water determined by DLS. 
 
Given the relatively moderate FMPDL values for P(OEGMA-co-MPDL) copolymers, water-
solubility of OEGMA was expected to dominate over hydrophobicity from MPDL units, and 
thus preferentially lead to fully water-soluble polymer prodrugs. To validate this hypothesis, 
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Gem-P(OEGMA-co-MPDL) prodrugs with increasing contents of MPDL (P1–P3) were 
nanoprecipitated in water and the amount of nanoparticles, likely formed by nanoscale 
aggregation of amphiphilic P(OEGMA-co-MPDL) copolymers, was quantified by 
measurement of the dry content after ultracentrifugation (see experimental part and Table S3). 
The weight fraction of nanoparticles was estimated to maximum 16 wt.% for the copolymer 
containing the highest amount of MPDL (FMPDL = 0.25) to less than 1 wt.% for the one with 
the lowest amount (FMPDL = 0.06).  
 
Drug release in human serum 
The Gem release kinetics from the two different classes of polymer prodrugs was evaluated in 
human serum to better mimic the biological environment of the human body compared to 
accelerated degradation conditions (Figure 7). In all cases, the maximum drug release was 
reached after a period of ~1 h which is rather fast but commonly seen with water-soluble 
amide prodrugs.
65
 It is also believed that having a hydrophilic drug like Gem promotes a fast 
drug release compared to hydrophobic ones, for instance like paclitaxel, as already 
observed.
12
 Interestingly, after the maximum drug release is reached, a plateau is observed 
which likely corresponds to the fraction of drug that is not easily accessible and that cannot be 
readily cleaved from the copolymers within the time frame of the drug release experiment. 
We can hypothesize for P(MMA-co-MPDL) nanoparticles that only the surface fraction of 
Gem is released whereas the fraction which is buried into the nanoparticle’s core will be 
accessible and released only when the nanoparticles are degraded.
66
 As for soluble 
P(OEGMA-co-MPDL) prodrugs, which are essentially molecularly dissolved even for the 
highest amounts of MPDL (Figure S18), they will form a protective P(OEGMA-co-MPDL) 
shroud wrapped around the drug, efficiently protecting the drug-linker moiety from enzymes, 
similarly to what is observed with PEGylated peptides/proteins. Therefore, only the fraction 
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of Gem located at the periphery of such a PEG-based random coil will be readily cleaved 
whereas the remaining amount of drug will be accessible after the copolymer gets degraded.
66
  
 
 
Figure 7. Gem release profiles at 37 °C in human serum from (a) Gem-P(OEGMA-co-
MPDL) (P1-P3), (b) Gem-digly-P(OEGMA-co-MPDL) (P1d-P3d), (c) Gem-P(MMA-co-
MPDL) (P4-P6) and (d) Gem-digly-P(MMA-co-MPDL) (P4d-P6d). 
 
For Gem-P(OEGMA-co-MPDL) P1–P3, the total Gem release gradually increased from ~7 to 
~25 % when decreasing FMPDL from 0.25 to 0.06 (Figure 7a). This may be explained by the 
strong hydrophobic nature of MPDL that prevents enzyme access because of poor solvation of 
the drug-polymer linker and/or π-π stacking interactions between M DL units. Analogous 
copolymers with the diglycolate linker (P1d–P3d) led to the same trend but with a 
significantly higher Gem release; from ~33 % for FMPDL = 0.22 to ~70 % for FMPDL = 0.07 
(Figure 7b), likely because of the increased hydrophilicity and decreased steric hindrance 
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nearby the amide bond. Replacing OEGMA by MMA in the polymer prodrug structures (P4–
P6 and P4d–P6d) led to the exact same trend but with significantly lower Gem release 
contents. Gem-P(MMA-co-MPDL) nanoparticles P4–P6 led to nearly no Gem release (< 2 
%) whereas Gem-digly-P(MMA-co-MPDL) nanoparticles (P4d–P6d) allowed final Gem 
release contents to reach 7–13 % (Figure 7c and d). This may be explained not only by the 
detrimental effect of hydrophobic MMA units nearby the Gem-polymer linker, but also by the 
nanoparticulate nature of the polymer prodrug itself, both preventing extensive water uptake 
and/or enzyme access.  
Altogether, these results showed that Gem release was independently governed by: (i) 
the MPDL content –the lower the MPDL content, the greater the Gem release; (ii) the nature 
of the linker –the presence of the diglycolate linker enabled a greater Gem release compared 
to a simple amide bond and (iii) the hydrophilicity of the methacrylate monomer –OEGMA 
enabled a greater Gem release compared to MMA. It is therefore suggested that increasing the 
hydrophilicity nearby the drug-polymer linkage, by using OEGMA and/or from decreasing 
the amount of inserted MPDL, which is a very hydrophobic monomer, had a beneficial 
influence on the Gem release. Regarding the diglycolate linker, its beneficial impact may be 
explained by: (i) its higher lability compared to a single amide bond that may enable its rapid 
cleavage and (ii) its connection to the amide bond that may promote the amide bond 
accessibility to enzymes.  
 
In vitro anticancer activity 
A crucial question is whether the above-mentioned drug release trends observed in human 
serum directly correlate with anticancer activity of the polymer prodrugs. The cell viability of 
two cancer cell lines corresponding to clinically relevant cancer models for Gem, human lung 
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carcinoma (A549) and human pancreatic cancer (MiaPaCa-2), was then determined after 
incubation with the different polymer prodrugs at various concentrations.  
Gem-free control copolymers, P(OEGMA-co-MPDL) P7 and P(MMA-co-MPDL) P8, 
were not cytotoxic for all concentrations tested while free Gem exhibited half maximal 
inhibitory concentrations (IC50) of 4 nM and 14 nM for A549 and MiaPaCa-2 cells, 
respectively. When increasing the MPDL fraction, IC50 values of Gem-P(OEGMA-co-MPDL) 
P1–P3 increased from 0.30 to 2.14 M for A549 cells and from 0.13 to 1.07 M for 
MiaPaCa-2 cells (Figure 8), which is totally in line with the previously-mentioned trends 
observed from drug release experiments. As expected from drug release experiments, 
diglycolate-containing polymer prodrugs (P1d–P3d) gave the same trend but were 
significantly more cytotoxic, leading to IC50 values 5-8-fold lower for A549 cells (Figure 8a 
and 8b) to 3–4-fold lower for MiaPaCa-2 cells (Figure 8c and 8d) compared to those obtained 
from P1–P3. Note that the small fraction of Gem-P(OEGMA-co-MPDL) nanoparticles 
contained with the soluble Gem-P(OEGMA-co-MPDL) copolymer did not affect the MTT 
results as a purified aqueous solution of copolymers P2 gave the same cytotoxicity profile 
(Figure S19). 
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Figure 8. Cell viability (MTT test) with increasing concentrations of (a, c) Gem-P(OEGMA-
co-MPDL) (P1–P3) and P(OEGMA-co-MPDL) (P7, Control) or (b, d) Gem-digly-
P(OEGMA-co-MPDL) (P1d–P3d) and P(OEGMA-co-MPDL) (P7, Control) on (a, b) A549 
cells and (c, d) MiaPaCa-2 cells. 
 
Also, in agreement with drug release experiments, Gem-P(MMA-co-MPDL) P4–P6 and 
Gem-digly-P(MMA-co-MPDL) P4d–P6d polymer prodrug nanoparticles (Figure 9) were 
always less cytotoxic than OEGMA-based counterparts. Importantly, whatever the cell line, 
no decrease in cell viability was obtained for P4–P6 even at the highest concentrations, 
whereas the use of the diglycolate linker enabled the corresponding prodrugs to be cytotoxic, 
especially for those containing less MPDL (P5d and P6d, see Figure 9b and 9d). As 
suggested from drug release experiments, this trend may be correlated with a too high 
hydrophobicity nearby the Gem-polymer linker, but also to the nanoparticulate nature of the 
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polymer prodrugs that, conversely to fully water-soluble counterparts, were less accessible to 
water/enzymes, thus preventing efficient release of Gem (only surface exposed Gem-digly 
moieties were likely accessible for cleavage). Note that, in general, higher cytotoxicity was 
observed against MiaPaCa-2 cells, with nearly complete cell death. This is explained by the 
fact that A549 cells are known to exhibit some resistance against Gem, as evidenced by a 
plateau at 20 % of cell viability.
67
 Even though results with Gem-P(MMA-co-MPDL) and 
Gem-digly-P(MMA-co-MPDL) nanoparticles may appear somewhat disappointing, they are 
crucial to identify key structural parameters to improve the cytotoxicity of the materials. 
 
 
Figure 9. Cell viability (MTT test) with increasing concentrations of (a, c) Gem-P(MMA-co-
MPDL) (P4–P6) and P(MMA-co-MPDL) (P8, Control) or (b, d) Gem-digly-P(MMA-co-
MPDL) (P4d–P6d) and P(MMA-co-MPDL) (P8, Control) on (a, b) A549 cells and (c, d) 
MiaPaCa-2 cells. 
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In a nutshell, the results on both cell lines were in excellent agreement with those obtained 
from drug release experiments: (i) polymer prodrugs based on P(OEGMA-co-MPDL) were 
more cytotoxic than those based on P(MMA-co-MPDL); (ii) increasing the MPDL fraction in 
the copolymers led to a decrease in cytotoxicity and (iii) polymer prodrugs based on the 
diglycolate linker were significantly more cytotoxic than those based on a single amide 
linkage (see Table S4 for all IC50 values). Remarkably, the best candidates, Gem-digly-
P(OEGMA-co-MPDL) P1d enabled to reach the cytotoxic activity of free Gem. 
 
Conclusion 
Degradable vinyl polymer prodrugs were designed by “drug-initiated” NMrROP of a 
methacrylic ester monomer with MPDL from an alkoxyamine derivatized with Gem as an 
anticancer drug. Two libraries of polymer prodrugs differing by the nature of the methacrylic 
ester monomer (OEGMA or MMA), the nature of the drug-polymer linker and the MPDL 
content were prepared. Whereas MMA-based prodrugs formed highly stable nanoparticles 
upon nanoprecipitation, OEGMA-based prodrugs were water-soluble. The degradation of the 
copolymer prodrugs was proved under accelerated conditions (i.e., basic hydrolysis) and the 
degradation level was finely tuned by adjusting the MPDL content. Drug-release profiles in 
human serum and in vitro anticancer activity against two different cancer cell lines helped to 
establish structure/activity relationships and select the most favorable structural parameters 
for having the best activity. We demonstrated that three structural parameters independently 
governed the anticancer activity: (i) soluble OEGMA-based prodrugs were more cytotoxic 
than MMA-based counterpart; (ii) the lower the MPDL content, the greater the anticancer 
activity and (iii) a diglycolate linker gave a greater activity compared to a simple amide bond.  
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Overall, this unique approach enabled to combine the best of different worlds: (i) 
degradability from ring-opening polymerization; (ii) ease of synthesis from a radical 
polymerization method and (iii) sustained drug release and high anticancer activity from a 
prodrug approach. Additionally, this approach is versatile and general as it could easily be 
extended to other polymers, to other pathologies by using different drugs, and to other 
biologically relevant molecules (e.g., fluorescent dye, imaging agent) for theranostic 
applications. 
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